slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,369
Current window 34,201-34,230
Pages 1,379
Rows per page 30
Component
34,201-34,230 of 41,369
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
The slide uses a four-column structure to explain the target, molecular nature, preclinical results, and clinical status.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The slide uses a column-based layout to compare four distinct medical conditions, each with specific patient counts and development milestones.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
Includes before/after patient photos and comparative data against Mogamulizumab.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
Includes visual longitudinal data (photos) and quantitative bar chart data.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
26
Includes a timeline diagram for the study phases and a target product profile comparison.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
30
Includes a disclaimer regarding the source of financial data (Form 10-Q).Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a simple list-based timeline format.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations 1 hit
09
The slide uses a 'Good, Better, Best' framework to organize the company's product portfolio.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · Product1 hit
15
FGI Industries | Investor Presentation Deck | 30 slidesFGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
20
The slide uses a combination of tables and a central callout to illustrate TAM vs SAM.FGI Industries | Investor Presentation Deck | 30 slides · FGI Industries
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
The slide compares mPFS results against SOC-AURELIA and ELAHARE benchmarks.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
11
The slide uses a table to compare clinical outcomes across patient subgroups (all, resistant, refractory) and a callout box for key takeaways.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
Waterfall plot and spider plot used to visualize clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
14
Includes a Kaplan-Meier plot with a table comparing historical data to VIRO-15 trial results.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
16
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two distinct therapeutic approaches (oncolytic immunotherapy and adoptive cell therapy).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
The slide uses a document-style callout for key takeaways and circular image containers for facility locations.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
The slide categorizes the library into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
25
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
27
Includes specific financial metrics and analyst names.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
33
The slide uses a dual-axis chart to correlate tumor size (SLD) and biomarker (CA-125) response to the Olvi-Vec intervention.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
05
The slide uses a combination of summary text, callouts for specific financial impacts, and detailed tables for per-day sales and organic growth metrics.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
17
Includes a commentary section explaining the nature of the adjustments (A-E).GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of the NXC-201 CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit